The patent follows previous approvals granted in China and New Zealand as well as new dietary ingredient status in the US and novel food approval in the European Union.
Further process and efficacy patents are pending in other international jurisdictions.
CardiaBeat, derived from an omega-3 glyceride matrix, has been shown to reduce the likelihood of cardiovascular disease in clinical trials.